Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells

Molecular Pharmacology

Volumn 63, Issue 2, 2003, Pages 342-350

  Fossetta, James ^a   Jackson, James ^a   Deno, Gregory ^a   Fan, Xuedong ^a   Du, Xixuan Karen ^a   Bober, Loretta ^a   Soudé Bermejo, Anne ^a   De Bouteiller, Odette ^a   Caux, Christophe ^a   Lunn, Charles ^a   Lundell, Daniel ^a   Palmer, R Kyle ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO N6 (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CALCIUM; LIPOPOLYSACCHARIDE; N (2 METHOXYPHENYL) N [2 (3 PYRIDYL)QUINAZOLIN 4 YL]UREA; N6 (3 IODO 4 AMINOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; N6 (4 AMINOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; PERTUSSIS TOXIN; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VUF 5574;

ARTICLE; BINDING SITE; CALCIUM SIGNALING; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIGAND BINDING; MONOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOSINE; BINDING SITES; CALCIUM; CELL MEMBRANE; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IODINE RADIOISOTOPES; MONOCYTES; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1;

EID: 0037308772     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.2.342     Document Type: Article

References (42)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, and Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811.
2. Banchereau J and Steinman RM (1998) Dendritic cells and the control of immunity. Nature (Lond) 392:245-252.
3. Baraldi PG and Borea PA (2000) New potent and selective human adenosine A3 receptor antagonists. Trends Pharmacol Sci 21:456-459.
4. Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, Brambilla R, Cattabeni F, Jacobson KA, and Franceschi C (1998) Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. Neurochem Int 32:493-504.
5. Bleharski J, Niazi K, Sieling P, Cheng G, and Modlin R (2001) Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J Immunol 167:3174-3181.
6. Bouma MG, Jeunhomme TM, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FA, and Buurman WA (1997) Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol 158:5400-5408.
7. Broussas M, Cornillet-Lefebvre P, Potron G, and Nguyen P (1999) Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J Leukoc Biol 66:495-501.
8. Caux C, Ait-Yahia S, Chemin K, de Bouteiller O, Dieu-Nosjean MC, Homey B, Massacrier C, Vanbervliet B, Zlotnik A, and Vicari A (2000) Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345-369.
9. Christopoulos A, Parsons AM, Lew MJ, and El-Fakahany EE (1999) The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 382:217-227.
10. Conklin BR, Farfel Z, Lustig KD, Julius D, and Bourne HR (1993) Sunstitution of three amino acids switches receptor specificity of Gqα to that of Giα. Nature (Lond) 363:274-276.
11. Cooper J, Hill S, and Alexander SPH (1997) An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells. Br J Pharmacol 122:546-550.
12. Dubois B, Bridon JM, Fayette J, Barthelemy C, Banchereau J, Caux C, and Briere F (1999) Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 66:224-230.
13. Ezeamuzie C and Phillips E (1999) Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br J Pharmacol 127:188-194.
14. Ferguson G, Watterson KR, and Palmer TM (2000) Subtype-specific kinetics of inhibitory adenosine receptor internalization are determined by sensitivity to phosphorylation by G protein-coupled receptor kinases. Mol Pharmacol 57:546-552.
15. Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela EI, and Lluis C (1997) Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 52:283-294.
16. Fredholm B, IJzerman A, Jacobson K, Klotz K-N, and Linden J (2001a) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
17. Fredholm B, Irenius E, Kull B, and Schulte G (2001b) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448.
18. Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, Baraldi PG, and Borea PA (2002) A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol 61:415-424.
19. Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G, and Borea PA (2001) Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br J Pharmacol 134:116-126.
20. Hasko G, Nemeth Z, Vizi ES, Salzman A, and Szabo C (1998) An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur J Pharmacol 358:261-268.
21. Hasko G, Szabo C, Nemeth Z, Kvetan V, Pastores SM, and Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNFα and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 157:4634-4640.
22. Kenakin T (1997a) Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 18:456-464.
23. Kenakin T (1997b) Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed, pp 366-369, Lippincott-Raven Publishers, Philadelphia.
24. Klotz K-N (2000) Adenosine receptors and their ligands. Naunyn-Schniedeberg's Arch Pharmacol 362:382-391.
25. Klotz K-N, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, and Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schniedeberg's Arch Pharmacol 357:1-9.
26. Kohno Y, Ji X, Mawhorter SD, Koshiba M, and Jacobson KA (1996) Activation of A3 adenosine receptors on human eosinophils elevates intracellular calcium. Blood 88:3569-3574.
27. 2+ mobilization by muscarinic antagonists. Biochem Biophys Res Commun 243:41-46.
28. Lew MJ, Ziogas J, and Christopoulos A (2000) Dynamic mechanisms of non-classical antagonism by competitive AT1 receptor antagonists. Trends Pharmacol Sci 21:376-381.
29. Lipscomb MF and Masten BJ (2002) Dendritic cells: immune regulators in health and disease. Physiol Rev 82:97-130.
30. Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, and Borea PA (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol 134:1215-1226.
31. Murphree LJ, Marshall MA, Reiger JM, MacDonald TL, and Linden J (2002) Human A2A adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gβ4. Mol Pharmacol 61:455-462.
32. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, and Norgauer J (2001) Expression and function of adenosine receptors in human dendritic cells. FASEB J 15:1963-1970.
33. Sajjadi F, Takabayashi K, Foster A, Domingo R, and Firestein G (1996) Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol 156:3435-3442.
34. Salvatore C, Jacobson M, Taylor H, Linden J, and Johnson R (1993) Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 90:10365-10369.
35. Salvatore C, Tilley A, Latour A, Fletcher D, Koller B, and Jacobson M (2000) Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275:4429-4434.
36. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, and Liu YJ (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science (Wash DC) 284:1835-1837.
37. Sullivan GW and Linden J (1998) Role of A2A adenosine receptors in inflammation. Drug Dev Res 45:103-112.
38. Trincavelli ML, Tuscano D, Cecchetti P, Falleni A, Benzi L, Klotz KN, Gremigni V, Cattabeni F, Lucacchini A, and Martini C (2000) Agonist-induced internalization and recycling of the human A3 adenosine receptors: role in receptor desensitization and resensitization. J Neurochem 75:1493-1501.
39. Varani K, Cacciari B, Baraldi PG, Dionisotti S, Ongini E, and Borea PA (1998) Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors. Life Sci 63:PL 81-87.
40. 3H]MRE 3008F20: a novel antagonist radio-ligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol 57:968-975.
41. Yang Q and Lanier SM (1999) Influence of G protein type on agonist efficacy. Mol Pharmacol 56:651-656.
42. Zal T, Volkmann A, and Stockinger B (1994) Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen. J Exp Med 180:2089-2099.